iLite® RANKL Assay Ready Cells
BM4052
This iLite® RANKL reporter assay enables precise quantification of RANKL activity or blockade in a cell-based system. Supports evaluation of osteoimmunology-targeting therapeutics.
- High sensitivity and large dynamic range
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
- Normalization of cell counts and serum matrix effects using a second reporter gene
Product Overview
The iLite® RANKL Assay Ready Cells can be used for the quantification of RANKL activity, RANKL inhibitor activity or immunogenicity studies and determination of neutralizing antibody response against RANKL inhibitors in test samples, including human serum.
iLite® RANKL Assay Ready Cells are human HEK293* cells genetically engineered and optimized to be responsive to human soluble RANK Ligand (RANKL), resulting in a proportional expression of Firefly Luciferase. Normalization of cell counts, and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promotor.
*The HEK-293 cell line has been used under a license obtained from AdVec Inc.
FOR RESEARCH USE ONLY
How it works
The function of iLite assays
iLite cells have receptors on the cell surface that can bind to the marker under study.
What's in the box?
>250 µL of Assay Ready Cells suspended in cryoprotective medium.
Specifications
| Product code | BM4052 |
| Assay target | RANKL |
| Size | 1 vial corresponding to one 96 well plate |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
Documents
Application Note
